Transforming European Food Systems with multi-actor networks and Living Labs through the FoodSHIFT Approach.

Our current global Food System is facing extraordinary challenges in both size and severity, including a rise in unsustainable consumption behaviours, continued environmental degradation, growing food insecurity, and widening social inequalities. A Food System transformation is now both critically important and overwhelmingly complex, requiring nothing less than a complete overhaul of the entire value chain. Everyone is needed: Small Medium Enterprises (SMEs) with technological solutions, Non-Governmental Organisations (NGOs) with social innovations, researchers with novel methodologies, governments with food policy advancements, professionals with varying expertise, and last but not least, empowered and informed citizens with the ability and resources for better decision-making.

The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience.

The aim of the present study was to evaluate the safety and efficacy of radionuclide therapy with [Lu]Lu-DOTA-TATE according to our single center experience at the University of Naples Federico II. For the present analysis, we considered 21 patients with progressive, advanced, well-differentiated G1 and G2 in patients with gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs) treated with [Lu]Lu-DOTA-TATE according to the decisions of a multidisciplinary team. All patients underwent four cycles of 7-8 GBq of [Lu]Lu-DOTA-TATE every 8 weeks.

Replacement of Native with Malted Triticale (x Wittmack) Flour in Dry Pasta: Technological and Nutritional Implications.

The use of native and malted triticale (MT) flour in dry pasta has been limited despite the potential of triticale in cereal-based food production. In this study, triticale-based dry spaghetti with increasing levels of substitution (0, 25, 50, and 75 g/100 g /) of MT flour were formulated and analyzed. Samples were analyzed for technological and nutritional traits, including the in vitro starch and protein digestions.

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer.

Background: Differentiated thyroid cancer (DTC) patients have an outstanding overall long-term survival rate, and certain subsets of DTC patients have a very high likelihood of disease recurrence. Radioactive iodine (RAI) therapy is a cornerstone in DTC management, but cancer cells can eventually develop resistance to RAI. Radioactive iodine-refractory DTC (RAIR-DTC) is a condition defined by ATA 2015 guidelines when DTC cannot concentrate RAI ab initio or loses RAI uptake ability after the initial therapy.